… The Cancer and Leukemia Group B trial 30406 was a randomized phase 2 clinical trial
that investigated erlotinib alone or with carboplatin and paclitaxel in patients with a history of …

… , randomized phase II trial examined the efficacy and safety of combination erlotinib plus
fulvestrant compared to erlotinib alone for … in PFS or OS with erlotinib plus fulvestrant among all …

… NSCLC, sunitinib plus erlotinib did not improve OS compared with erlotinib alone, but the …
In summary, in this global, randomized, phase III trial in patients with NSCLC previously …

… phase III trial, bevacizumab was added to erlotinib in patients with relapsed NSCLC. Although
PFS was improved with the combination compared with erlotinib alone … randomized phase …

… in four randomized phase III trials. In these studies, concurrent administration of erlotinib or
… not improve survival compared with chemotherapy alone. Preclinical evidence suggests that …

… This multicenter, randomized, phase III study investigated the efficacy of figitumumab plus
erlotinib compared with erlotinib alone in patients with pretreated, nonsmall-cell lung cancer (…

… study is that patients treated with erlotinib with bevacizumab and panitumumab had much
severe adverse events than those treated with erlotinib alone. Future study may be needed to …

… first phase 3 study to compare the efficacy of erlotinib plus bevacizumab with erlotinib alone
… The results from this interim analysis suggest that patients given bevacizumab and erlotinib …

… been solely the result of increased efficacy of erlotinib in never smokers and/or in patients …
We thus developed a randomized phase II trial to investigate the efficacy of erlotinib alone and …

… erlotinib is less toxic (8). Gefitinib showed a progression-free survival (PFS) advantage over
chemotherapy as a first-line therapy in 3 randomized phase III … neither agent alone, induced …